Replay, a biotechnology startup built around several gene therapy technologies, has launched the first of several planned spinouts, revealing on Monday a company named Eudora.
Replay is only three months from its own debut, having emerged in July with $55 million and a goal to overcome some of gene therapy’s current limitations. The company follows what it terms a “hub-and-spoke” model, aiming to share its technology across several companies, each working on a specific therapeutic area. At the time of its launch, Replay said it had already formed five “spoke” companies, including Eudora.
